What breaks when healthcare organisations do not test medical devices and internal networks together?

Why separate testing creates a false sense of coverage

When medical devices and internal networks are validated in isolation, teams can miss the actual path an attacker would use to cross from one to the other. That matters because the weakest control is often not the device or the network alone, but the handoff between them, where trust, routing, and segmentation assumptions meet.

In practice, this means a device can look acceptable in a lab while still becoming a pivot point once it sits on a real clinical network with shared services, flat segments, or permissive management paths. The test result is then technically true but operationally incomplete.

That gap is especially relevant in environments where endpoint hardening, segmentation, and identity controls are owned by different teams. A device review may prove local integrity, while a network test may prove perimeter or VLAN controls, but neither tells you whether the combined path supports lateral movement, credential reuse, or remote administration abuse.

What attackers exploit across device and network boundaries

The main problem is not just device compromise, it is the ability to chain that compromise into broader access. Once an attacker reaches a weakly protected device, they may use it to probe adjacent clinical systems, internal services, or operational technology that was never meant to be reachable from that starting point.

Healthcare makes that chain more dangerous because ransomware crews often care less about the first foothold than about speed to impact. If a device can talk to internal management systems, file shares, or poorly segmented application networks, the attacker gains options for propagation, data exposure, and service disruption.

This is where combined testing becomes more valuable than isolated control checks. A network test may show that segmentation exists on paper, while a device test may show that the device firmware is current. The real question is whether the two together still block attack progression under realistic conditions, including compromised credentials, misrouted traffic, and management exceptions.

What the test strategy should prove instead

The right objective is to validate the attack path end to end: device, surrounding network, and the controls that connect them. That means checking whether a compromised device can reach internal resources it should not, whether management ports are isolated, and whether segmentation still holds when devices use standard enterprise services.

It also means treating clinical continuity as part of the security design. If a device failure, quarantine action, or containment step would take down an operational service, the organisation has not really tested resilience, only connectivity. For that reason, combined testing should show both what is blocked and what must remain available during containment.

Good practice is to align this testing with the real environment, not a synthetic one. A meaningful exercise includes device classes, network zones, administrative paths, and the dependencies that sit between them. The point is to discover whether the environment contains hidden bridges that an attacker can use, not just whether each component meets its own checklist.

Risk and Threat Considerations

Separated testing leaves a blind spot that adversaries can exploit for lateral movement, especially where medical devices share trust relationships with internal services or administration paths. In healthcare, that can turn a single compromised endpoint into a route toward clinical disruption, ransomware spread, or access to sensitive operational systems.

Failure mechanism: A device passes its own security review, and the network passes its own segmentation review, but the combined environment still allows reachable management services, shared credentials, or permissive routes that support propagation.

Impact: Attackers can move from the initial weak point into adjacent systems, increasing the chance of ransomware impact, downtime, and loss of confidence in clinical continuity controls.

Practitioner Guidance

What to verify: Test the full attack path, not just individual assets. The most useful evidence is whether a compromised device can reach internal services, whether segmentation still holds under realistic traffic, and whether management access is genuinely isolated from patient-care workloads.

What good looks like: Security teams can show that a device compromise does not create a practical route into broader internal systems, and that containment actions do not collapse essential clinical operations. That is a stronger result than passing separate device and network checks.

Practitioner takeaway: If you do not test the boundary between the device and the network, you are only proving that each control works in isolation, not that the environment can resist real-world compromise chains.

Related resources from NHI Mgmt Group

• What breaks when healthcare organisations try to secure medical devices with legacy segmentation approaches?
• How should healthcare organisations secure remote access without exposing internal systems to untrusted devices and networks?
• What breaks in healthcare environments when segmentation is not in place for medical devices and hybrid IT networks?
• What breaks when healthcare organisations rely on 1-to-1 mobile devices for frontline nursing?